Table 7.
Comparison of efficacy of nanotherapy vs Bevacizumab. The efficacy of nanotherapy is shown to be better in patients with recurrent GBM.
| Type of Therapy | Nanotherapy | Bevacizumab | ||||
|---|---|---|---|---|---|---|
| Type of GB | Primary | Recurrent | Overall | Primary | Recurrent | Overall |
| No. of Patients | 66 | 159 | 225 | 637 | 548 | 1185 |
| mOS | 6.75 months | 9.7 months | 8.2 months | 15.7 months | 9.3 months | 12.5 months |
| Mean PFS | 2.3 months | 3.92 months | 3.11 months | 10.7 months | - | - |
| Macdonald criteria |
CR = 3.03%, PR = 4.54%, SD = 63.64% |
CR = 0.63%, PR = 5.66%, SD = 9.43% |
CR = 1.33%, PR = 5.33%, SD = 25.33% |
- | CR = 6.02%, PR = 49.09%, SD = 29.02% |
- |
mOS = median Overall Survival, PFS = Progression-Free Survival, CR = Complete Remission, PR = Partial Remission, SD = Standard Deviation.